{{Drugbox
| IUPAC_name = 3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid
| image = Cetraxate.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|cetraxate}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 34675-84-8
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 2680
| DrugBank =  
| ChemSpiderID = 2579
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5VPA8CPF0N
| KEGG = D07663
| ChEMBL = 502896

<!--Chemical data-->
| chemical_formula =  
| C=17 | H=23 | N=1 | O=4 
| molecular_weight = 305.36 g/mol
| smiles = O=C(O)CCc2ccc(cc2)OC(=O)C1CCC(CN)CC1
}}

'''Cetraxate''' ([[International Nonproprietary Name|INN]]) is an oral [[gastrointestinal]] [[medication]] which has a cytoprotective effect.<ref name="pmid3367546">{{cite journal |vauthors=Kurebayashi Y, Ikeda T, Osada Y |title=Cytoprotective action of cetraxate against HCl.ethanol-induced gastric lesion in rats |journal=Jpn. J. Pharmacol. |volume=46 |issue=1 |pages=17–25 |date=January 1988 |pmid=3367546 |doi= 10.1254/jjp.46.17|url=http://joi.jlc.jst.go.jp/JST.Journalarchive/jphs1951/46.17?from=PubMed}}</ref> Double-blind clinical trials in patients with gastric ulcer compared the effects of cetraxate with those of the drug [[gefarnate]], a common standard drug treatment for gastric ulcer. Endoscopic examinations of patients treated with cetraxate showed cure rates of 28% after 4 weeks, 61% after 8 weeks, and 73% after 12 weeks of treatment, significantly higher than cure rates seen with gefarnate at both 8 and 12 weeks.<ref name="pmid391240">{{cite journal |vauthors=Ishimori A, Yamagata S, Taima T |title=Effect of p-hydroxyphenyl-propionic ester of tranexamic acid hydrochloride (Cetraxate) on peptic ulcer. Multi-center clinical study |journal=Arzneimittelforschung |volume=29 |issue=10 |pages=1625–32 |year=1979 |pmid=391240 |doi= |url=}}</ref>

==References==
<references/>

{{Drugs for peptic ulcer and GORD}}

[[Category:Drugs acting on the gastrointestinal system and metabolism]]
[[Category:Amines]]
[[Category:Carboxylate esters]]
[[Category:Propionic acids]]


{{gastrointestinal-drug-stub}}